Department of Defense: Research Grant for Alzheimer’s Convergence Science

The intent of the FY18 PRARP CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission (see Section II.A, Program Description). The research impact for the FY18 PRARP CSRA is expected to benefit the military, Veteran, and civilian communities.

The FY18 PRARP CSRA is open to eligible applicants whose named Principal Investigators (PIs) are at or above the level of Assistant Professor (or equivalent) from any field or discipline. The application should demonstrate the study team’s experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI’s published work, pilot data, or from peer-reviewed literature.

The anticipated direct costs budgeted for the entire period of performance for an FY18 PRARP CSRA will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

FY18 PRARP CSRA Overarching Challenges: This FY18 PRARP CSRA funding opportunity requires applications to address one or more of the following FY18 PRARP CSRA Overarching Challenges:

Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.

Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

Diagnostic Technologies, Tests, Biomarkers, or Devices: The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

FY18 PRARP CSRA Focus Areas: In addition to addressing one or more of the specified FY18 PRARP CSRA Overarching Challenges, applications should address at least one of the following FY18 PRARP CSRA Focus Areas in support of the FY18 PRARP CSRA Overarching Challenges. An application that proposes research outside of the FY18 PRARP CSRA Focus Areas is acceptable, as long as the applicant provides a strong rationale:

Mechanisms of Pathogenesis: Identification of contributing mechanisms (e.g., diffuse/ traumatic axonal injury, roles of non-neuronal cells, neuroinflammation, immune regulation, biology/pathology of tau, vascular contributions, and omics techniques for examining mechanisms) associated with TBI and subsequent AD/ADRD pathogenesis.

Biomarkers: Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid-based, imaging-based, physiological, and omics techniques for biomarkers).

Epidemiological Research: Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD.

Novel Target Identification: Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents.

Note: Pharmacological interventions are specifically discouraged. A pharmacological intervention is defined as clinical research requiring investigational or U.S. Food and Drug Administration (FDA)-approved drugs or medicines.

The intent of the FY18 PRARP CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission (see Section II.A, Program Description). The research impact for the FY18 PRARP CSRA is expected to benefit the military, Veteran, and civilian communities.

The FY18 PRARP CSRA is open to eligible applicants whose named Principal Investigators (PIs) are at or above the level of Assistant Professor (or equivalent) from any field or discipline. The application should demonstrate the study team’s experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI’s published work, pilot data, or from peer-reviewed literature.

The anticipated direct costs budgeted for the entire period of performance for an FY18 PRARP CSRA will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

FY18 PRARP CSRA Overarching Challenges: This FY18 PRARP CSRA funding opportunity requires applications to address one or more of the following FY18 PRARP CSRA Overarching Challenges:

Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.

Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

Diagnostic Technologies, Tests, Biomarkers, or Devices: The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

FY18 PRARP CSRA Focus Areas: In addition to addressing one or more of the specified FY18 PRARP CSRA Overarching Challenges, applications should address at least one of the following FY18 PRARP CSRA Focus Areas in support of the FY18 PRARP CSRA Overarching Challenges. An application that proposes research outside of the FY18 PRARP CSRA Focus Areas is acceptable, as long as the applicant provides a strong rationale:

Mechanisms of Pathogenesis: Identification of contributing mechanisms (e.g., diffuse/ traumatic axonal injury, roles of non-neuronal cells, neuroinflammation, immune regulation, biology/pathology of tau, vascular contributions, and omics techniques for examining mechanisms) associated with TBI and subsequent AD/ADRD pathogenesis.

Biomarkers: Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid-based, imaging-based, physiological, and omics techniques for biomarkers).

Epidemiological Research: Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD.

Novel Target Identification: Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents.

Note: Pharmacological interventions are specifically discouraged. A pharmacological intervention is defined as clinical research requiring investigational or U.S. Food and Drug Administration (FDA)-approved drugs or medicines.

The intent of the FY18 PRARP CSRA is to support efforts to generate research resources, tools, or novel research efforts for researchers and/or practitioners in health sciences related to the PRARP’s mission (see Section II.A, Program Description). The research impact for the FY18 PRARP CSRA is expected to benefit the military, Veteran, and civilian communities.

The FY18 PRARP CSRA is open to eligible applicants whose named Principal Investigators (PIs) are at or above the level of Assistant Professor (or equivalent) from any field or discipline. The application should demonstrate the study team’s experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI’s published work, pilot data, or from peer-reviewed literature.

The anticipated direct costs budgeted for the entire period of performance for an FY18 PRARP CSRA will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

FY18 PRARP CSRA Overarching Challenges: This FY18 PRARP CSRA funding opportunity requires applications to address one or more of the following FY18 PRARP CSRA Overarching Challenges:

Paucity of Research Resources: The paucity of research resources to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities.

Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

Diagnostic Technologies, Tests, Biomarkers, or Devices: The need for technologies, tests, or devices to detect or prognose the progression to AD/ADRD subsequent to TBI. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI.

FY18 PRARP CSRA Focus Areas: In addition to addressing one or more of the specified FY18 PRARP CSRA Overarching Challenges, applications should address at least one of the following FY18 PRARP CSRA Focus Areas in support of the FY18 PRARP CSRA Overarching Challenges. An application that proposes research outside of the FY18 PRARP CSRA Focus Areas is acceptable, as long as the applicant provides a strong rationale:

Mechanisms of Pathogenesis: Identification of contributing mechanisms (e.g., diffuse/ traumatic axonal injury, roles of non-neuronal cells, neuroinflammation, immune regulation, biology/pathology of tau, vascular contributions, and omics techniques for examining mechanisms) associated with TBI and subsequent AD/ADRD pathogenesis.

Biomarkers: Development of strategies to diagnose, prognose, or characterize neurological changes or risk factors associated with TBI and subsequent AD/ADRD (e.g., fluid-based, imaging-based, physiological, and omics techniques for biomarkers).

Epidemiological Research: Research focusing on the incidence, distribution, and other factors relating to the health of individuals affected by TBI and subsequent AD/ADRD.

Novel Target Identification: Basic research (non-human) directly leading to the identification of new targets for the development of existing or new investigational medicines, drugs, or agents.

Note: Pharmacological interventions are specifically discouraged. A pharmacological intervention is defined as clinical research requiring investigational or U.S. Food and Drug Administration (FDA)-approved drugs or medicines.